Factors associated with serum high mobility group box 1 (HMGB1) levels in a general population

Metabolism: Clinical and Experimental

Volumn 58, Issue 12, 2009, Pages 1688-1693

  Fukami, Ako ^a   Adachi, Hisashi ^a   Yamagishi, Sho ichi ^a   Matsui, Takanori ^a   Ueda, Shin ichiro ^a   Nakamura, Kazuo ^a   Enomoto, Mika ^a   Otsuka, Maki ^a   Kumagae, Shun ichi ^a   Nanjo, Yasuki ^a   Kumagai, Eita ^a   Esaki, Eishi ^a   Murayama, Kyoko ^a   Hirai, Yuji ^a   Imaizumi, Tsutomu ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; HIGH MOBILITY GROUP B1 PROTEIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION;

ADULT; AGED; ALCOHOL DRINKING; ANTHROPOMETRY; DIABETES MELLITUS; FEMALE; HEMODYNAMICS; HMGB1 PROTEIN; HUMANS; KIDNEY FUNCTION TESTS; LEUKOCYTE COUNT; LIPIDS; MALE; MIDDLE AGED; POPULATION; RECEPTORS, IMMUNOLOGIC; SEX FACTORS; SMOKING; SOCIOECONOMIC FACTORS;

EID: 71849085213     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.05.024     Document Type: Article

References (31)

1. Rauvala H., and Pihlaskari R. Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. J Biol Chem 262 (1987) 16625-16635
2. Andersson U., Erlandsson-Harris H., Yang H., and Tracey K.J. HMGB1 as a DNA-binding cytokine. J Leukoc Biol 72 (2002) 1084-1091
3. Klune J.R., Dhupar R., Cardinal J., Billiar T.R., and Tsung A. HMGB1: endogenous danger signaling. Mol Med 14 (2008) 476-484
4. Andersson U., Wang H., Palmblad K., et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med 192 (2000) 565-570
5. Wang H., Yang H., and Tracey K.J. Extracellular role of HMGB1 in inflammation and sepsis. J Intern Med 255 (2004) 320-331
6. Wang H., Bloom O., Zhang M., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285 (1999) 248-251
7. Yang H., Ochani M., Li J., et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci U S A 101 (2004) 296-301
8. Kokkola R., Li J., Sundberg E., et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 48 (2003) 2052-2058
9. Wang H., Liao H., Ochani M., et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 10 (2004) 1216-1221
10. Gaini S., Pedersen S.S., Koldkjaer O.G., Pedersen C., and Moller H.J. High mobility group box-1 protein in patients with suspected community-acquired infections and sepsis: a prospective study. Crit Care 11 (2007) R32
11. Sunden-Cullberg J., Norrby-Teglund A., Rouhiainen A., et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 33 (2005) 564-573
12. Yamada S., Yakabe K., Ishii J., Imaizumi H., and Maruyama I. New high mobility group box 1 assay system. Clin Chim Acta 372 (2006) 173-178
13. Goldstein R.S., Gallowitsch-Puerta M., Yang L., et al. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock 25 (2006) 571-574
14. Hatada T., Wada H., Nobori T., et al. Plasma concentrations and importance of High Mobility Group Box protein in the prognosis of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 94 (2005) 975-979
15. Hori O., Brett J., Slattery T., et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 270 (1995) 25752-25761
16. Schmidt A.M., Yan S.D., Yan S.F., and Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108 (2001) 949-955
17. Huttunen H.J., Fages C., Kuja-Panula J., Ridley A.J., and Rauvala H. Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res 62 (2002) 4805-4811
18. Fiuza C., Bustin M., Talwar S., et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101 (2003) 2652-2660
19. Huttunen H.J., and Rauvala H. Amphoterin as an extracellular regulator of cell motility: from discovery to disease. J Intern Med 255 (2004) 351-366
20. Schlueter C., Hauke S., Flohr A.M., Rogalla P., and Bullerdiek J. Tissue-specific expression patterns of the RAGE receptor and its soluble forms-a result of regulated alternative splicing?. Biochim Biophys Acta 1630 (2003) 1-6
21. Taguchi A., Blood D.C., del Toro G., et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 405 (2000) 354-360
22. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 196 (2008) 9-21
23. Imai E., Horio M., Nitta K., et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 11 (2007) 41-50
24. Bruchfeld A., Qureshi A.R., Lindholm B., et al. High Mobility Group Box Protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med 14 (2008) 109-115
25. Soro-Paavonen A., Watson A.M., Li J., et al. Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 57 (2008) 2461-2469
26. Park L., Raman K.G., Lee K.J., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4 (1998) 1025-1031
27. Falcone C., Emanuele E., D'Angelo A., et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25 (2005) 1032-1037
28. Tan K.C., Shiu S.W., Chow W.S., Leng L., Bucala R., and Betteridge D.J. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 49 (2006) 2756-2762
29. Nakamura K., Yamagishi S., Nakamura Y., et al. Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc Res 70 (2005) 137-141
30. Geroldi D., Falcone C., and Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 13 (2006) 1971-1978
31. Santilli F., Bucciarelli L., Noto D., et al. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med 43 (2007) 1255-1262